159 related articles for article (PubMed ID: 22645700)
21. Randomized, double-blind phase II trial of Lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis.
Kingsnorth AN; Galloway SW; Formela LJ
Br J Surg; 1995 Oct; 82(10):1414-20. PubMed ID: 7489182
[TBL] [Abstract][Full Text] [Related]
22. Interleukin 1 receptor antagonist and E-selectin concentrations: a comparison in patients with severe acute pancreatitis and severe sepsis.
Hynninen M; Valtonen M; Markkanen H; Vaara M; Kuusela P; Jousela I; Piilonen A; Takkunen O
J Crit Care; 1999 Jun; 14(2):63-8. PubMed ID: 10382785
[TBL] [Abstract][Full Text] [Related]
23. Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.
De Backer D
Drug Saf; 2007; 30(11):995-1010. PubMed ID: 17973539
[TBL] [Abstract][Full Text] [Related]
24. Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C.
Yan SB; Nelson DR
Crit Care Med; 2004 May; 32(5 Suppl):S239-46. PubMed ID: 15118525
[TBL] [Abstract][Full Text] [Related]
25. Upregulated but insufficient generation of activated protein C is associated with development of multiorgan failure in severe acute pancreatitis.
Lindstrom O; Kylanpaa L; Mentula P; Puolakkainen P; Kemppainen E; Haapiainen R; Fernandez JA; Griffin JH; Repo H; Petaja J
Crit Care; 2006 Feb; 10(1):R16. PubMed ID: 16420659
[TBL] [Abstract][Full Text] [Related]
26. Neutrophil surface expression of CD11b and CD62L in diabetic microangiopathy.
Mastej K; Adamiec R
Acta Diabetol; 2008 Sep; 45(3):183-90. PubMed ID: 18496641
[TBL] [Abstract][Full Text] [Related]
27. Expanded CD14
Zhang R; Shi J; Zhang R; Ni J; Habtezion A; Wang X; Hu G; Xue J
J Immunol; 2019 May; 202(9):2578-2584. PubMed ID: 30894427
[TBL] [Abstract][Full Text] [Related]
28. Activated protein C in severe acute pancreatitis without sepsis? Not just yet ..
Shankar-Hari M; Wyncoll D
Crit Care; 2010; 14(4):188. PubMed ID: 20707935
[TBL] [Abstract][Full Text] [Related]
29. Neutrophil and monocyte activation in chronic kidney disease patients under hemodialysis and its relationship with resistance to recombinant human erythropoietin and to the hemodialysis procedure.
Pereira R; Costa E; Gonçalves M; Miranda V; do Sameiro Faria M; Quintanilha A; Belo L; Lima M; Santos-Silva A
Hemodial Int; 2010 Jul; 14(3):295-301. PubMed ID: 20649681
[TBL] [Abstract][Full Text] [Related]
30. The effect of activated protein C on experimental acute necrotizing pancreatitis.
Yamanel L; Mas MR; Comert B; Isik AT; Aydin S; Mas N; Deveci S; Ozyurt M; Tasci I; Unal T
Crit Care; 2005 Jun; 9(3):R184-90. PubMed ID: 15987389
[TBL] [Abstract][Full Text] [Related]
31. Differential neuroprotection and risk for bleeding from activated protein C with varying degrees of anticoagulant activity.
Wang Y; Thiyagarajan M; Chow N; Singh I; Guo H; Davis TP; Zlokovic BV
Stroke; 2009 May; 40(5):1864-9. PubMed ID: 19057019
[TBL] [Abstract][Full Text] [Related]
32. Triggering receptor expressed on myeloid cells-1 expression on monocytes is associated with inflammation but not with infection in acute pancreatitis.
Ferat-Osorio E; Wong-Baeza I; Esquivel-Callejas N; Figueroa-Figueroa S; Duarte-Rojo A; Guzmán-Valdivia-Gómez G; Rodea-Rosas H; Torres-González R; Sánchez-Fernández P; Arriaga-Pizano L; López-Macías C; Robles-Díaz G; Isibasi A
Crit Care; 2009; 13(3):R69. PubMed ID: 19442309
[TBL] [Abstract][Full Text] [Related]
33. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.
Ely EW; Laterre PF; Angus DC; Helterbrand JD; Levy H; Dhainaut JF; Vincent JL; Macias WL; Bernard GR;
Crit Care Med; 2003 Jan; 31(1):12-9. PubMed ID: 12544987
[TBL] [Abstract][Full Text] [Related]
34. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
[TBL] [Abstract][Full Text] [Related]
35. Soluble CD14 receptor expression and monocyte heterogeneity but not the C-260T CD14 genotype are associated with severe acute pancreatitis.
Rahman SH; Salter G; Holmfield JH; Larvin M; McMahon MJ
Crit Care Med; 2004 Dec; 32(12):2457-63. PubMed ID: 15599151
[TBL] [Abstract][Full Text] [Related]
36. Readministration of drotrecogin alfa (activated) in an adult with severe sepsis.
Scipione MR; Nogid B; Davanos E; DiGregorio RV
Am J Health Syst Pharm; 2011 Sep; 68(18):1711-5. PubMed ID: 21880886
[TBL] [Abstract][Full Text] [Related]
37. Static and dynamic assessment of biomarkers in surgical patients with severe sepsis.
Lowry SF; Awad S; Ford H; Cheadle W; Williams MD; Qualy RL; McCollam JS; Bates BM; Fry DE;
Surg Infect (Larchmt); 2004; 5(3):261-8. PubMed ID: 15684797
[TBL] [Abstract][Full Text] [Related]
38. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment.
Vincent JL; Bernard GR; Beale R; Doig C; Putensen C; Dhainaut JF; Artigas A; Fumagalli R; Macias W; Wright T; Wong K; Sundin DP; Turlo MA; Janes J
Crit Care Med; 2005 Oct; 33(10):2266-77. PubMed ID: 16215381
[TBL] [Abstract][Full Text] [Related]
39. An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures.
Betancourt M; McKinnon PS; Massanari RM; Kanji S; Bach D; Devlin JW
Pharmacoeconomics; 2003; 21(18):1331-40. PubMed ID: 14750900
[TBL] [Abstract][Full Text] [Related]
40. Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis.
Johnson CD; Kingsnorth AN; Imrie CW; McMahon MJ; Neoptolemos JP; McKay C; Toh SK; Skaife P; Leeder PC; Wilson P; Larvin M; Curtis LD
Gut; 2001 Jan; 48(1):62-9. PubMed ID: 11115824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
